Seattle Children’s: First In-Human T-Cell Clinical Trial to Extend Remission for Children With Leukemia

In a press release from 5/9, Seattle Children’s Hospital has announced results from a phase 1 pilot study showing “T-cell immunotherapy to be effective in getting 93 percent of patients with relapsed or refractory acute lymphoblastic leukemia (ALL) into complete initial remission.”

This pilot, the Seattle Children’s Pediatric Leukemia Adoptive Therapy (PLAT-02) trial opens the door for a PLAT-03 trial, where patients will receive “booster” infusions of a second T-cell product, called T antigen-presenting cells (T-APCs). The hope of the next pilot is to help put patients in long-term remission. Read more at: Seattle Children’s Hospital Website.


Published by

Dave Bove

Innovation Lover, Singer, Actor, Songwriter, Guitarist (poor one), Artist, Computer Geek, and Jolly (sometimes) Rancher...

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s